Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
The Biology of Sex and Sport.
Urinary polyomavirus: novel biomarker of congenital ureteropelvic junction obstruction.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 07; 38(7):3724-3742.
View in:
PubMed
subject areas
Humans
Immunologic Factors
Magnetic Resonance Imaging
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Natalizumab
Treatment Outcome